Tower Research Capital LLC (Trc) Oncternal Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.28 - $0.64 $4,022 - $9,194	-14,366 Reduced 74.33%	4,962 $2,000
Q3 2023 Nov 14, 2023	SELL	$0.29 - $0.48 $2,864 - $4,740	-9,876 Reduced 33.82%	19,328 $5,000
Q2 2023 Aug 14, 2023	BUY	$0.28 - $0.79 $4,192 - $11,827	14,972 Added 105.2%	29,204 $9,000
Q1 2023 May 09, 2023	BUY	$0.63 - $1.3 $8,966 - $18,501	14,232 New	14,232 $11,000
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.56 $14,656 - $32,663	-20,938 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.37 - $2.43 $9,010 - $15,982	6,577 Added 45.8%	20,938 $29,000
Q4 2021 Feb 14, 2022	BUY	$2.27 - $4.39 $21,900 - $42,354	9,648 Added 204.71%	14,361 $33,000
Q3 2021 Nov 15, 2021	SELL	$3.37 - $4.76 $11,478 - $16,212	-3,406 Reduced 41.95%	4,713 $19,000
Q2 2021 Aug 16, 2021	BUY	$4.75 - $9.39 $7,519 - $14,864	1,583 Added 24.22%	8,119 $39,000
Q1 2021 May 17, 2021	SELL	$4.59 - $9.04 $145,016 - $285,609	-31,594 Reduced 82.86%	6,536 $54,000
Q4 2020 Feb 16, 2021	BUY	$1.51 - $6.3 $55,412 - $231,191	36,697 Added 2560.85%	38,130 $187,000
Q3 2020 Nov 16, 2020	BUY	$1.7 - $3.28 $2,436 - $4,700	1,433 New	1,433 $2,000
Q2 2020 Aug 13, 2020	SELL	$2.43 - $3.23 $94 - $125	-39 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$2.49 - $4.39 $1,003 - $1,769	-403 Reduced 91.18%	39 $0
Q4 2019 Feb 07, 2020	SELL	$3.75 - $6.11 $13,335 - $21,727	-3,556 Reduced 88.94%	442 $2,000
Q3 2019 Nov 05, 2019	BUY	$3.87 - $6.13 $10,998 - $17,421	2,842 Added 245.85%	3,998 $20,000
Q2 2019 Aug 13, 2019	BUY	$4.86 - $9.24 $5,618 - $10,681	1,156 New	1,156 $8,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.